SSY Group (HKG:2005) said its 5-milliliter Composite Potassium Hydrogen Phosphate Injection and 5-milligram Vortioxetine Hydrobromide Tablets have obtained the National Medical Products Administration of China's approval for drug production and registration, a Monday Hong Kong bourse filing said.
The said injection is a compound used for the correction of hypophosphatemia in adult and child patients and parenteral nutrition in adult and child patients when enteral nutrition is impossible or insufficient.
The tablet is used for the treatment of depression in adults and has already obtained bulk drug approval from the authorities.
With the said approvals, the injection and the tablet, being under type 3 and type 4 chemical drugs respectively, are regarded as having passed the consistency evaluation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.